Multifunctional drugs for endothelial dysfunction in diabetes and glaucoma.
Endothelial dysfunction is a multifactorial term in that it encompasses a number of complex biochemical alterations in the ability of endothelial cells to perform their normal physiological function. These alterations are generally initiated by increased oxidative stress leading to pathological alterations in the cellular balance of mediators produced by endothelial cells. The key mediators include nitric oxide (NO), superoxide and endothelin. This review presents the current status of our knowledge of endothelial dysfunction in diabetes and in glaucoma and presents the case for evaluation of multifunctional drugs in these diseases.
Wood
Paul L
PL
OxoN Medica Inc, 385 Oyster Point Boulevard, Suite 9A, South San Francisco, CA 94080, USA. pwood@oxonmedica.com
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D016232:Endothelins / Q000037:antagonists & inhibitors; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D052250:Nitric Oxide Synthase Type III; D009799:Ocular Physiological Phenomena / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D016232:Endothelins; D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D020030:Nitric Oxide Donors; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III